Pfizer's COVID vaccine could gain full government approval by January 2022 at the latest, according to the FDA.
July 19, 2021 -- The U.S. Food and Drug Administration has granted priority review status to the Pfizer/BioNTech coronavirus vaccine for people 16 and up, meaning the two-shot vaccine could gain full government approval by January 2022 at the latest.. The review “has been ongoing, is among the highest priorities of the agency, and the agency intends to complete the review far in advance” of January 2022, the release said.
The Pfizer vaccine has been administered to people 16 and up under an emergency use authorization since mid-December. It was the first vaccine authorized by the government and is the most widely used in the United States. Pfizer and its European partner BioNTech sought full approval by applying for a Biologics License Application in May. They’ve been submitting information on a rolling basis since then. The vaccine had already gone through rigorous clinical trials to receive the EUA.
Full approval would benefit the drug companies by allowing the vaccines to stay on the market once the COVID-19 pandemic is no longer considered an emergency, former FDA commissioner Robert Califf, MD, toldlast May. The companies could also market the vaccine directly to consumers, something they cannot do under an EUA, he said.
The number of COVID-19 cases, hospitalizations, and deaths have been driven down since the national vaccination program started in December. Still, less than half the U.S. population is fully vaccinated, according to the CDC.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Pfizer Shot Just 39% Effective Against Delta Infection, But Largely Prevents Severe Illness, Israel Study SuggestsI am a London-based reporter for Forbes covering breaking news. Previously, I have worked as a reporter for a specialist legal publication covering big data and as a freelance journalist and policy analyst covering science, tech and health. I have a master’s degree in Biological Natural Sciences and a master’s degree in the History and Philosophy of Science from the University of Cambridge. Follow me on Twitter theroberthart or email me at rhartforbes.com
Leer más »
WSJ News Exclusive | Covid-19 Pill Race Heats Up as Japanese Firm Vies With Pfizer, MerckJapan’s Shionogi has started human trials for a once-a-day drug designed to neutralize the coronavirus in less than a week as Pfizer and Merck carry out later-stage tests.
Leer más »
U.S. Buys 200 Million Covid-19 Vaccines From Pfizer and BioNTech at About $24 a ShotThe U.S. is paying about $24 a dose, according to Pfizer, up from the $19.50 that the government paid in its earlier deals. The deal brings the total purchased from the U.S. to 1 billion doses.
Leer más »
Arkansas, Ohio govs hope FDA full approval of COVID vaccine will increase inoculation rate'My concern is that...some people are not being vaccinated who would be vaccinated and those people are going to die,' Ohio Gov. Mike DeWine said.
Leer más »
Biden administration purchases extra Pfizer doses to prepare for possibility of children vaccine needs and booster shotsThe Biden administration purchased an additional 200 million doses of Pfizer-BioNTech's Covid-19 vaccine to prepare for potential additional vaccine needs in the US, an administration official familiar with the contract tells CNN.
Leer más »
Pfizer Covid-19 Vaccine Is Less Effective Against Delta Infections but Still Prevents Serious Illness, Israel Study SuggestsData from Israel suggests Pfizer’s vaccine has become less effective in preventing infection of Covid-19 in recent weeks, although it remains a robust bulwark against serious illness as governments scramble to respond to the spread of the Delta variant
Leer más »